Sentinel: the two peptides quietly reshaping immune modulation

The peptide news cycle in 2025 was dominated by metabolic agents - Tirzepatide, Retatrutide, the next generation of GLP-1s. Quietly, in clinical research rooms, two immune peptides regained relevance. Thymosin Alpha-1 and LL-37 are both older than most readers know. Both are doing something interesting again.

Thymosin Alpha-1: a forty-year history#

Thymosin Alpha-1 (TA-1) is a 28-amino-acid peptide isolated from thymus tissue in the 1970s by Allan Goldstein. It has been approved as a therapeutic drug - under the name Zadaxin - in more than 30 countries since the 1990s, primarily for chronic hepatitis B and C, certain cancers, and immune compromise.

Mechanistically, it acts on T-cell maturation and dendritic cell function. In an immunocompromised state, it pushes the system back toward balance - supporting Th1 responses where needed, modulating regulatory T-cell function where appropriate.

It is not FDA-approved in the United States, despite the international clinical record. That is an artifact of how the FDA handles peptides developed abroad, not a comment on the safety profile.

What changed recently#

TA-1 received a wave of clinical attention during the COVID-19 era, where it was studied as an adjunct therapy in severe cases. Several observational studies reported lower mortality, but a 2023 meta-analysis pooling the trial data found no statistically significant overall mortality benefit - with possible signals limited to severe and older-patient subgroups. The proposed mechanism was consistent with TA-1's historical use: rebalancing a dysregulated immune response.

Outside of viral infection, current research is examining TA-1 in sepsis, post-chemotherapy immune recovery, and chronic immune dysfunction syndromes.

LL-37: your body's own antimicrobial peptide#

LL-37 is a cathelicidin - an endogenous antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells. It is part of innate immunity, present in roughly every mucosal surface and tissue in your body, and it does two distinct things.

First, direct antimicrobial action. LL-37 disrupts bacterial cell membranes through a mechanism that pathogens have struggled to develop resistance against - because resistance would require fundamental changes to lipid composition.

Second, immune signaling. LL-37 recruits and activates immune cells, modulates inflammation, and - importantly - disrupts bacterial biofilms. Biofilm-forming pathogens (think chronic sinusitis, certain wound infections, dental infections) are notoriously hard to treat because antibiotics do not penetrate biofilms well. LL-37 does.

Why pair them#

TA-1 and LL-37 act on orthogonal parts of the immune system. TA-1 modulates adaptive immunity - T-cells, dendritic cells, the slow-but-specific arm. LL-37 acts on innate immunity - direct microbial action and the fast, broad response.

In states of chronic immune dysfunction - whether from stress, illness, age, or treatment - both arms tend to be impaired. Sentinel addresses both.

What this stack is not#

• A vaccine or anti-infective.
• A replacement for medical treatment of active infection.
• A stimulant or a way to "boost" a healthy immune system.

Sentinel is research-oriented immune modulation. The use cases are specific: chronic stress, post-illness recovery, immune dysfunction. The mechanism is supported by decades of clinical and preclinical research. The market is small. The science is real.